aldosterone has been researched along with Dyslipidemias in 12 studies
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim of the study is to evaluate the impact of spironolactone (SPL) on indexes of metabolic syndrome (MS) and further investigate the mechanisms underlying its protective effects." | 7.79 | Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. ( Liang, LY; Lin, YE; Liu, MJ; Long, HD; Zeng, ZH, 2013) |
| "These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism." | 3.85 | Activation of cardiac renin-angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder. ( Kim, IK; Olatunji, LA; Seok, YM; Usman, TO, 2017) |
| "Aim of the study is to evaluate the impact of spironolactone (SPL) on indexes of metabolic syndrome (MS) and further investigate the mechanisms underlying its protective effects." | 3.79 | Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. ( Liang, LY; Lin, YE; Liu, MJ; Long, HD; Zeng, ZH, 2013) |
| "Torcetrapib was the first CETP inhibitor to enter a large-scale, prospective, placebo-controlled interventional trial, which was prematurely terminated in December 2006 because of excess cardiovascular and noncardiovascular mortality in the active treatment group." | 2.44 | Spotlight on HDL-raising therapies: insights from the torcetrapib trials. ( Chapman, MJ; Guérin, M; Kontush, A, 2008) |
| "Arterial hypertension is one of the major coronary risk factors for cardiovascular diseases." | 2.43 | [Hypertension in postmenopausal women --selected pathomechanisms]. ( Kawecka-Jaszcz, K; Pośnik-Urbańska, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Walther, R | 1 |
| Julius, U | 1 |
| Tselmin, S | 1 |
| Schatz, U | 1 |
| Bornstein, SR | 1 |
| Graessler, J | 1 |
| Haas, AV | 1 |
| Baudrand, R | 2 |
| Easly, RM | 1 |
| Murray, GR | 1 |
| Touyz, RM | 1 |
| Pojoga, LH | 2 |
| Jeunemaitre, X | 2 |
| Hopkins, PN | 2 |
| Rosner, B | 1 |
| Williams, JS | 1 |
| Williams, GH | 2 |
| Adler, GK | 2 |
| Ohno, Y | 1 |
| Sone, M | 1 |
| Inagaki, N | 1 |
| Yamasaki, T | 1 |
| Ogawa, O | 1 |
| Takeda, Y | 1 |
| Kurihara, I | 1 |
| Umakoshi, H | 1 |
| Ichijo, T | 1 |
| Katabami, T | 1 |
| Wada, N | 1 |
| Ogawa, Y | 1 |
| Yoshimoto, T | 1 |
| Kawashima, J | 1 |
| Watanabe, M | 1 |
| Matsuda, Y | 1 |
| Kobayashi, H | 1 |
| Shibata, H | 1 |
| Miyauchi, S | 1 |
| Kamemura, K | 1 |
| Fukuoka, T | 1 |
| Yamamoto, K | 1 |
| Otsuki, M | 1 |
| Suzuki, T | 1 |
| Naruse, M | 1 |
| Long, HD | 1 |
| Lin, YE | 1 |
| Liu, MJ | 1 |
| Liang, LY | 1 |
| Zeng, ZH | 1 |
| Hall, JE | 1 |
| do Carmo, JM | 1 |
| da Silva, AA | 1 |
| Wang, Z | 1 |
| Hall, ME | 1 |
| Olatunji, LA | 1 |
| Usman, TO | 1 |
| Seok, YM | 1 |
| Kim, IK | 1 |
| Gupta, N | 1 |
| Garza, AE | 1 |
| Vaidya, A | 1 |
| Leopold, JA | 1 |
| Ferri, C | 1 |
| Romero, JR | 1 |
| Williams, J | 1 |
| Loscalzo, J | 1 |
| Pimenta, E | 1 |
| Calhoun, DA | 1 |
| Giordano, R | 1 |
| Marinazzo, E | 1 |
| Berardelli, R | 1 |
| Picu, A | 1 |
| Maccario, M | 1 |
| Ghigo, E | 1 |
| Arvat, E | 1 |
| King, AJ | 1 |
| Olivier, NB | 1 |
| Mohankumar, PS | 1 |
| Lee, JS | 1 |
| Padmanabhan, V | 1 |
| Fink, GD | 1 |
| Pośnik-Urbańska, A | 1 |
| Kawecka-Jaszcz, K | 1 |
| Kontush, A | 1 |
| Guérin, M | 1 |
| Chapman, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for aldosterone and Dyslipidemias
| Article | Year |
|---|---|
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
Topics: Aldosterone; Animals; Antihypertensive Agents; Dyslipidemias; Heart Conduction System; Hemodynamics; | 2015 |
[Hypertension in postmenopausal women --selected pathomechanisms].
Topics: Age Factors; Aldosterone; Angiotensin II; Blood Pressure; Body Mass Index; Dyslipidemias; Estrogen R | 2006 |
Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Tr | 2008 |
9 other studies available for aldosterone and Dyslipidemias
| Article | Year |
|---|---|
Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Blood Component Removal; Cholesterol, LDL; Dehydroep | 2019 |
Interplay Between Statins, Cav1 (Caveolin-1), and Aldosterone.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Caveolin 1; Cholesterol; Correlation of Data; Dyslipide | 2020 |
Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.
Topics: Adult; Aldosterone; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Essential Hypertensio | 2018 |
Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways.
Topics: Aldosterone; Animals; Apoptosis; Diet, High-Fat; Dyslipidemias; Hypertension; Insulin-Secreting Cell | 2013 |
Activation of cardiac renin-angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder.
Topics: Aldosterone; Animals; Ataxia Telangiectasia Mutated Proteins; Cardiovascular Diseases; Contraceptive | 2017 |
Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Aldehyde Reductase; Aldosterone; Animals; Blood Glucose; Ca | 2016 |
Aldosterone and metabolic dysfunction: an unresolved issue.
Topics: Aldosterone; Animals; Dyslipidemias; Humans; Hyperaldosteronism; Hypertension; Hypokalemia | 2009 |
Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas.
Topics: Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Aldosterone; B | 2010 |
Hypertension caused by prenatal testosterone excess in female sheep.
Topics: Aldosterone; Animals; Blood Pressure; Chlorides; Cholesterol; Disease Models, Animal; Dyslipidemias; | 2007 |